Back to News
Market Impact: 0.3
Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationM&A & Restructuring
Tempest Therapeutics announced an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral vector platform. The deal expands Tempest's technology access for developing in vivo CAR-T therapies targeting cancer and autoimmune disease, though no financial terms or development milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
TPST0.45
More News
- US official says upcoming spectrum auctions could generate more than $100 billion
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Fed delivers its first hike in 3 years. Plus, what's moving Starbucks and GE Vernova
- AI Buildout Hits Inflation as Fed Hikes Rates
- OpenAI discloses six more instances of ’concerning’ AI model behavior
- The Competition's Response to Tesla Robotaxi Day
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard